
Dr Mark Fendrick on the Potential Impact of IRA Drug Price Negotiation Provision on Commercial Plans
It's hard to predict whether the Medicare drug price negotiation provision in the Inflation Reduction Act (IRA) could lead to higher or lower prices in the commercial market, said A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.




























